



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Ogalvibart

Cat. No.:	HY-145644
CAS No.:	2599039-60-6
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Ogalvibart (C-135-LS) is a human anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model <sup>[1]</sup> .								
IC <sub>50</sub> & Target	SARS-CoV-2 <sup>[1]</sup> .								
In Vivo	<p>Ogalvibart (C-135-LS; 10 mg/kg; 75 days before infection) in combination with 10 mg/kg C144LS can effectively block development of COVID-19 in the rhesus disease model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Rhesus macaques (3-11 years old)<sup>[1]</sup>.</td></tr><tr><td>Dosage:</td><td>10 mg/kg (in combination with 10 mg/kg C144LS)</td></tr><tr><td>Administration:</td><td>75 days before infection</td></tr><tr><td>Result:</td><td>Protected a subset of animals whose infectious challenge was 75 days post administration from disease.</td></tr></table>	Animal Model:	Rhesus macaques (3-11 years old) <sup>[1]</sup> .	Dosage:	10 mg/kg (in combination with 10 mg/kg C144LS)	Administration:	75 days before infection	Result:	Protected a subset of animals whose infectious challenge was 75 days post administration from disease.
Animal Model:	Rhesus macaques (3-11 years old) <sup>[1]</sup> .								
Dosage:	10 mg/kg (in combination with 10 mg/kg C144LS)								
Administration:	75 days before infection								
Result:	Protected a subset of animals whose infectious challenge was 75 days post administration from disease.								

### REFERENCES

[1]. Beddingfield BJ, et al. Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. Front Cell Infect Microbiol. 2021 Nov 18;11:753444.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA